Multiple studies have shown that MyD88 has tumor-promoting effects in colorectal cancer [27], primary and metastatic breast cancer [28], Waldenstrom macroglobulinemia (WM) [29], gastric cancer [25], epithelial ovarian cancer [30], mutated diffuse large B-cell lymphoma (DLBCL) [31], breast cancer [7,32], liver cancer [33], lung cancer [34], skin cancer [7], pancreatic cancer [7], and other cancers. This evidence concerns the gene MYD88 and diffuse large B-cell lymphoma.